Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne, Jan; Delmas, Yahsou; Fakhouri, Fadi; Licht, Christoph; Lommelé, Åsa; Minetti, Enrico E; Provôt, François; Rondeau, Eric; Sheerin, Neil S; Wang, Jimmy; Weekers, Laurent E; Greenbaum, Larry A.
; 20(1): 125, 2019 04 10.
Artigo em Inglês | MEDLINE | ID: mdl-30971227
Tromboticheskaia mikroangiopatiia glaza pri atipichnom gemolitiko-uremicheskom sindrome (klinicheskoe nabliudenie).
Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition.
Genetic background of atypical hemolytic-uremic syndrome and its influence on the course of disease and therapeutic effects
Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?
Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
[Incomplete thrombotic microangiopathy as a variant of hemolytic-uremic syndrome].
When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension.
Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.